What Changed for Flu Billing in the 2026-2027 Season?
As of September 2026, flu season billing for family medicine practices has three changes that require workflow updates before the first shot goes into an arm. The FDA approved mFlusiva (Moderna), the first mRNA influenza vaccine, on August 5, 2026, for adults aged 50 and older, which adds a new vaccine product to the formulary with its own CPT code. The AAFP issued independent 2026-2027 respiratory virus vaccine recommendations on September 2, 2026, filling a guidance gap left by the CDC after the Advisory Committee on Immunization Practices (ACIP) did not issue updated recommendations for this season. All three influenza vaccine virus components changed for the 2026-2027 formulations, meaning practices must stock and bill the updated seasonal products.
New vaccine product: mFlusiva (Moderna) is the first mRNA flu vaccine, approved for adults 50+. It carries its own CPT product code and requires a new line in your charge capture system.
Independent guidance: AAFP issued its own 2026-2027 flu recommendations on September 2 after ACIP did not release updated guidance. CDC carried over the 2025 recommendations.
Medicare covers flu shots at 100%: Medicare Part B covers the flu vaccine and its administration with no deductible, no copay, and no coinsurance. Bill the product code plus 90471. No patient cost sharing applies.
What Is New for 2026-2027
The 2026-2027 flu season introduced three developments that directly affect how family medicine practices stock, administer, and bill influenza vaccines.
First, the FDA approved mFlusiva (Moderna) on August 5, 2026, as the first mRNA-based influenza vaccine for adults aged 50 years and older. This is a fundamentally different platform from the traditional egg-based and cell-based flu vaccines that family medicine practices have billed for decades. mFlusiva carries its own CPT product code, distinct from the existing influenza vaccine product codes. Practices that choose to stock this vaccine must add the new code to their charge capture system and confirm that each payer covers the mRNA formulation before administering it.
Second, the AAFP, along with the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America, issued independent vaccine recommendations for the 2026-2027 respiratory virus season on September 2, 2026. This step was necessary because ACIP did not issue new guidance for this season. The CDC published interim clinical considerations on September 1 that carried over the 2025 recommendations, but did not include information about the newly approved mRNA flu vaccine. The AAFP’s recommendations specifically note that adults 65 and older should preferentially receive a high-dose, recombinant, adjuvanted, or the new mRNA influenza vaccine.
Third, all three influenza vaccine virus components changed for the 2026-2027 season. The World Health Organization selected new strains for the Northern Hemisphere formulation, which means every 2025-2026 vaccine remaining in a practice’s refrigerator is outdated and must not be administered or billed. Only 2026-2027 formulation vaccines should be stocked, and each carries the CPT product code specific to its type and manufacturer.
How Does the mRNA Flu Vaccine Affect Billing?
The mRNA flu vaccine (mFlusiva) introduces a new product code to a vaccine category that family medicine practices have billed the same way for years. Each flu vaccine type has its own CPT product code, and mFlusiva’s code is distinct from the codes for egg-based, cell-based, recombinant, and adjuvanted formulations. The administration code remains 90471 for the first injection. The billing pair is the same as any other flu shot: product code plus administration code.
The operational challenge is that mFlusiva is approved only for adults 50 and older. A practice that stocks mFlusiva alongside a standard egg-based vaccine for patients under 50 must ensure the charge capture matches the product actually given. Billing the mFlusiva product code when the standard vaccine was administered, or vice versa, creates a product-to-code mismatch that payers will deny.
In our experience matching family medicine practices with billing partners, multi-product vaccine billing is where practices lose the most revenue during flu season. When three or four flu vaccine products are in the refrigerator, the charge capture must track which product went into which patient. A billing partner that builds the product-code linkage into the EHR workflow prevents the mismatch before the claim goes out. For a detailed guide on immunization administration billing, see our guide on CPT 99213 for E/M visits that pair with vaccine administration.
Flu Vaccine Product Code Comparison
The table below maps the major flu vaccine types available for the 2026-2027 season with their billing characteristics.
| Vaccine Type | Age Group | Medicare Coverage | Admin Code |
|---|---|---|---|
| Standard egg-based (IIV) | 6 months+ | Part B, no cost sharing | 90471 |
| Cell-based (ccIIV) | 6 months+ | Part B, no cost sharing | 90471 |
| High-dose (HD-IIV3) | 65+ preferred | Part B, no cost sharing | 90471 |
| Adjuvanted (aIIV3) | 65+ preferred | Part B, no cost sharing | 90471 |
| Recombinant (RIV) | 18+ | Part B, no cost sharing | 90471 |
| mRNA (mFlusiva) | 50+ (new for 2026) | Part B, no cost sharing | 90471 |
| Intranasal (LAIV3) | 2-49 years | Part B, no cost sharing | 90473 |
Note: Each vaccine type has its own CPT product code assigned by the AMA. The administration code is the same across all injectable vaccines (90471 for first, 90472 for each additional). The intranasal vaccine uses 90473. Confirm the specific product code for each vaccine you stock through your CPT reference or EHR vendor before flu season begins.
Flu season billing gets more complex every year, and 2026-2027 adds the first mRNA flu vaccine, a guidance gap from ACIP, and new product codes to the mix. If your billing team cannot track which product code matches which vaccine for each patient, a family medicine billing partner who can prevents the denials before they start. Family Med Billers connects family medicine practices with vetted billing companies, free.
How to Prepare for Flu Season Billing
These steps should be completed before your practice begins administering 2026-2027 flu vaccines.
1. Confirm which flu vaccine products your practice will stock for the 2026-2027 season. Remove any remaining 2025-2026 formulations from your inventory.
2. Add the correct CPT product code for each vaccine to your EHR charge capture system. Verify the code against the AMA CPT reference for the 2026-2027 season.
3. If stocking mFlusiva (mRNA flu vaccine), add its specific product code and set an age restriction in the system for patients 50 and older only.
4. Verify payer coverage for each vaccine product. Medicare Part B covers all flu vaccines at 100% with no cost sharing. Medicare Advantage and commercial plans may have formulary preferences.
5. Train clinical staff on charge capture for multi-product vaccine administration. The person giving the shot must record which specific product was used so the billing team can match the correct product code.
6. For patients 65 and older, follow the AAFP recommendation to preferentially offer high-dose, recombinant, adjuvanted, or mRNA flu vaccine. Document which product was offered and administered.
Why Flu Season Billing Errors Compound
Providers often come to us after a flu season where hundreds of vaccine claims denied because the product code did not match the vaccine administered, the administration code was missing, or the lot number was not documented. At 200 to 500 flu shots per season in a typical family medicine practice, even a 5% error rate generates 10 to 25 denials that each require staff time to correct and resubmit.
The revenue per flu shot is modest: approximately $25 to $30 for the administration plus the vaccine product reimbursement, which varies by formulation but typically falls between $15 and $50 under Medicare Part B. The total per injection is roughly $40 to $80. But across hundreds of injections per season, flu shot revenue represents $8,000 to $40,000 in annual collections for a family medicine practice. Missing 5% of that to billing errors is $400 to $2,000 in preventable losses.
Across the billing companies we vet for family medicine practices, the consistent finding is that flu season billing errors are template problems, not coding problems. The practice knows the correct codes. The problem is that the EHR template links the wrong product code to the wrong vaccine, or the charge capture workflow does not distinguish between the three or four products in the refrigerator. A billing partner who builds the product-code linkage into the workflow before flu season starts prevents the entire category of errors. To see how the 2027 Medicare payment changes affect family medicine reimbursement, see our 2027 Medicare payment changes breakdown.
Frequently Asked Questions
Does Medicare cover the flu vaccine at no cost to the patient?
Yes. Medicare Part B covers the seasonal influenza vaccine and its administration at 100% with no deductible, no copay, and no coinsurance. This applies to all flu vaccine formulations including the new mRNA vaccine. Bill the product code plus 90471. Do not collect patient cost sharing.
What is mFlusiva and how do I bill it?
mFlusiva is the first mRNA influenza vaccine, manufactured by Moderna and approved by the FDA on August 5, 2026, for adults aged 50 and older. It has its own CPT product code. Bill it with 90471 for administration, the same as any other injectable flu vaccine.
Did the CDC issue new flu guidance for 2026-2027?
The CDC published interim clinical considerations on September 1, 2026, carrying over the 2025 flu recommendations. ACIP did not issue updated guidance for this season. The AAFP issued its own independent recommendations on September 2, 2026, alongside AAP, ACOG, and IDSA.
Which flu vaccine should I offer patients 65 and older?
The AAFP recommends that adults 65 and older preferentially receive a high-dose (HD-IIV3), recombinant (RIV3), adjuvanted (aIIV3), or mRNA (mFlusiva) influenza vaccine. If none of these are available, any age-appropriate flu vaccine should be used rather than delaying vaccination.
Can I still use 2025-2026 flu vaccine?
No. All three virus components changed for the 2026-2027 formulation. Any remaining 2025-2026 vaccine is outdated and must not be administered or billed. Stock only 2026-2027 formulation products.
Can I bill the flu vaccine with an E/M visit on the same date?
Yes. The flu vaccine administration (90471) can be billed alongside an E/M visit (such as 99213 or 99214) when the visit is separately identifiable and documented. The vaccine does not require a separate E/M visit, but if the provider performs one, both can be billed.
Next Steps
For E/M coding that pairs with flu shot administration, see our guide on CPT 99213.
To see how the 2027 Medicare changes affect family medicine, see our 2027 payment changes breakdown.
If your practice stocks multiple flu vaccine products and your billing team cannot track which code goes with which vaccine, get matched with a family medicine billing partner who builds the workflow before flu season starts.
The 2026-2027 flu season adds a new mRNA vaccine, a guidance gap from ACIP, and a multi-product billing challenge that family medicine practices handle hundreds of times between now and March. Family Med Billers connects your practice with vetted billing companies that build flu season charge capture correctly from the start. Across all 50 states, with rates starting as low as 2.95%. Comparing quotes is 100% free for providers.
